药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Mecasermin
Carlumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Carlumab.
Mecasermin
Intetumumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Intetumumab.
Mecasermin
Ibalizumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Ibalizumab.
Mecasermin
Lumretuzumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Lumretuzumab.
Mecasermin
Tovetumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Tovetumab.
Mecasermin
Dacetuzumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Dacetuzumab.
Mecasermin
Bimagrumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Bimagrumab.
Mecasermin
Blosozumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Blosozumab.
Mecasermin
Mavrilimumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Mavrilimumab.
Mecasermin
Plozalizumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Plozalizumab.
Mecasermin
Mogamulizumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Mogamulizumab.
Mecasermin
Bococizumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Bococizumab.
Mecasermin
Indusatumab vedotin
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Indusatumab vedotin.
Mecasermin
Fresolimumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Fresolimumab.
Mecasermin
Dusigitumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Dusigitumab.
Mecasermin
Fezakinumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Fezakinumab.
Mecasermin
Ensituximab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Ensituximab.
Mecasermin
Tanezumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Tanezumab.
Mecasermin
Labetuzumab govitecan
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Labetuzumab govitecan.
Mecasermin
Vanucizumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Vanucizumab.